Mediwound Ltd

NASDAQ:MDWDUnited States

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Contact Information

Headquarters

42 Hayarkon StreetYAVNE, Israel 8122745

Phone

---

Fax

---

Executives

Independent Chairman of the Board

Nachum Shamir

Chief Executive Officer, Director

Ofer Gonen

Chief Financial Officer

Hani Luxenburg

Chief Operating Officer, Chief Commercial Officer

Shmulik Hess

Executive Vice President, General Counsel, Corporate Secretary

Yaron Meyer